Department of Pediatrics, Faculty of Medicine, The Hashemite University, Zarqa, Jordan.
Institute of Endocrinology and Diabetes, The Children's Hospital at Westmead, University of Sydney, Australia.
Med Arch. 2024;78(2):154-158. doi: 10.5455/medarh.2024.78.154-158.
Familial non-autoimmune hyperthyroidism is a rare disorder characterized by the absence of thyroid autoimmunity, particularly TSH receptor antibody [TRAb].
The aim of this study was to describe a novel TSHR mutation identified in a family of two siblings and their father.
Two siblings presented for endocrine assessment at ages 7 and 14 years with mild T3 toxicosis, and the father presented at 30 years of age with non-autoimmune thyrotoxicosis. Both siblings were treated with oral antithyroid therapy to achieve reasonable symptom control and thyroid function normalization. The father was treated with oral antithyroid therapy, radioactive iodine, thyroidectomy, and thyroid replacement therapy. Peripheral blood DNA was extracted from both affected siblings and father. Mutation analysis of TSHR was carried out by PCR and Sanger sequencing of both strands of the extracted DNA.
Both siblings and their father were heterozygous for the missense TSHR variant c.1855G>C, p.[Asp619His], in exon 10.
This novel TSHR variant is associated with T3 toxicosis during childhood. Therefore, early identification and treatment may improve patient outcomes.
家族性非自身免疫性甲亢是一种罕见的疾病,其特征是缺乏甲状腺自身免疫,特别是 TSH 受体抗体(TRAb)。
本研究旨在描述一个新的 TSHR 突变,该突变发生在一个有两个兄弟姐妹及其父亲的家族中。
两个兄弟姐妹分别在 7 岁和 14 岁时因轻度 T3 毒性就诊,父亲在 30 岁时因非自身免疫性甲亢就诊。两个兄弟姐妹均接受了口服抗甲状腺治疗,以达到合理的症状控制和甲状腺功能正常化。父亲接受了口服抗甲状腺治疗、放射性碘治疗、甲状腺切除术和甲状腺替代治疗。从受影响的两个兄弟姐妹和父亲中提取外周血 DNA。通过 PCR 和提取 DNA 的双链 Sanger 测序对 TSHR 进行突变分析。
两个兄弟姐妹及其父亲均为 TSHR 外显子 10 中的错义变异 c.1855G>C,p.[Asp619His]的杂合子。
这个新的 TSHR 变体与儿童时期的 T3 毒性有关。因此,早期识别和治疗可能会改善患者的预后。